Novita Pharmaceuticals Announces Oral Presentation Of Phase 2 NP-G2-044 Data At The 2025 American Society For Clinical Oncology (ASCO) Annual Meeting

(MENAFN- PR Newswire)

NEW YORK, April 23, 2025 /PRNewswire/ -- Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through its proprietary fascin inhibitor technology, today announced that additional data from its Phase 2 Study of NP-G2-044 combined with anti-PD-1 therapy will be presented in an oral presentation as part of a Rapid Oral Session at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, being held May 30 to June 3, 2025, in Chicago, IL.

Details of the presentation are as follows:

Abstract Title: Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy.
Abstract Number: 2513
Session Type: Rapid Oral Abstract
Session Title: Developmental Therapeutics-Immunotherapy
Date and Time: June 1, 2025; 11:15 AM-12:45 PM CDT

About Novita's Pioneering Research in Fascin Inhibition

Cancer metastasis is the primary cause of over 90% of cancer-related deaths, yet there is currently no drug on the market specifically targeting metastasis. Furthermore, while Immuno-Oncology (IO) therapies, particularly immune checkpoint inhibitors, have made significant strides in cancer treatment, a large proportion of patients do not respond to existing IO treatments. Novita aims to address both of these critical medical needs by developing fascin inhibitors, which target a key protein involved in tumor cell motility and highly expressed in tumor cells and antigen-presenting cells within tumor tissues. The Company's lead asset, NP-G2-044, is a small-molecule fascin inhibitor that has demonstrated the ability to block metastasis in both preclinical and clinical studies. Additionally, when combined with immune checkpoint inhibitors, NP-G2-044 has demonstrated a unique ability to reinvigorate anti-tumor immune responses across multiple tumor types. Novita's multicenter Phase 2 clinical trial, titled "NP-G2-044 as Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies," is currently ongoing.

About Novita Pharmaceuticals, Inc.

Novita Pharmaceuticals, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing groundbreaking therapies using its proprietary fascin inhibitor technology to prevent and treat cancer metastasis while simultaneously enhancing anti-cancer immune responses. For more information, visit

Media Contact:

Argot Partners (media)

David Rosen

646.461.6387

[email protected]

Investor Contact:

Argot Partners (investors)

Sam Martin

212.600.1902

[email protected]

SOURCE Novita Pharmaceuticals, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN23042025003732001241ID1109463612